Cart
sales@molnova.com
KT-362 fumarate
CAS No. 105394-80-7
KT-362 fumarate( —— )
Catalog No. M34305 CAS No. 105394-80-7
KT-362 fumarate is a novel compound that acts as an antagonist of calcium channels, potassium channels and sodium channels.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 511 | In Stock |
|
| 5MG | 426 | In Stock |
|
| 10MG | 599 | In Stock |
|
| 25MG | 889 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKT-362 fumarate
-
NoteResearch use only, not for human use.
-
Brief DescriptionKT-362 fumarate is a novel compound that acts as an antagonist of calcium channels, potassium channels and sodium channels.
-
DescriptionKT-362 fumarate is a novel compound that acts as an antagonist of calcium channels, potassium channels and sodium channels.KT-362 fumarate causes vasodilation by affecting intracellular calcium mobilization in atrial muscle cells.KT-362 fumarate has a relaxing effect on femoral and basilar artery strips in rabbits.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetCalcium Channel
-
RecptorCalcium Channel | Potassium Channel | Sodium Channel
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number105394-80-7
-
Formula Weight516.61
-
Molecular FormulaC26H32N2O7S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(=C/C(O)=O)\C(O)=O.C(CCNCCC1=CC(OC)=C(OC)C=C1)(=O)N2C=3C(=CC=CC3)SCCC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
AMG1
A novel specific CRAC channel inhibitor that blocks function of effector.
-
Caldaret HCl
Caldaret HCl is an intracellular Ca2+ modulator that regulates calcium homeostasis at the sarcoplasmic reticulum and cell membrane, and can be used to study acute myocardial infarction and heart failure.
-
TTA-Q6
TTA-Q6, a selective T-type Ca2+ channel antagonist, exhibits potential antitumor and immunomodulatory activities for treating neurological disorders by inhibiting the uptake of extracellular calcium ions by tumor cells, thereby inducing intracellular calcium deficiency and endoplasmic reticulum (ER) stress.
